Faivre L, Collod-Beroud G, Loeys B L, Child A, Binquet C, Gautier E, Callewaert B, Arbustini E, Mayer K, Arslan-Kirchner M, Kiotsekoglou A, Comeglio P, Marziliano N, Dietz H C, Halliday D, Beroud C, Bonithon-Kopp C, Claustres M, Muti C, Plauchu H, Robinson P N, Adès L C, Biggin A, Benetts B, Brett M, Holman K J, De Backer J, Coucke P, Francke U, De Paepe A, Jondeau G, Boileau C
Centre de Génétique, Centre Hospitalier Universitaire, Dijon, France.
Am J Hum Genet. 2007 Sep;81(3):454-66. doi: 10.1086/520125. Epub 2007 Jul 25.
Mutations in the fibrillin-1 (FBN1) gene cause Marfan syndrome (MFS) and have been associated with a wide range of overlapping phenotypes. Clinical care is complicated by variable age at onset and the wide range of severity of aortic features. The factors that modulate phenotypical severity, both among and within families, remain to be determined. The availability of international FBN1 mutation Universal Mutation Database (UMD-FBN1) has allowed us to perform the largest collaborative study ever reported, to investigate the correlation between the FBN1 genotype and the nature and severity of the clinical phenotype. A range of qualitative and quantitative clinical parameters (skeletal, cardiovascular, ophthalmologic, skin, pulmonary, and dural) was compared for different classes of mutation (types and locations) in 1,013 probands with a pathogenic FBN1 mutation. A higher probability of ectopia lentis was found for patients with a missense mutation substituting or producing a cysteine, when compared with other missense mutations. Patients with an FBN1 premature termination codon had a more severe skeletal and skin phenotype than did patients with an inframe mutation. Mutations in exons 24-32 were associated with a more severe and complete phenotype, including younger age at diagnosis of type I fibrillinopathy and higher probability of developing ectopia lentis, ascending aortic dilatation, aortic surgery, mitral valve abnormalities, scoliosis, and shorter survival; the majority of these results were replicated even when cases of neonatal MFS were excluded. These correlations, found between different mutation types and clinical manifestations, might be explained by different underlying genetic mechanisms (dominant negative versus haploinsufficiency) and by consideration of the two main physiological functions of fibrillin-1 (structural versus mediator of TGF beta signalling). Exon 24-32 mutations define a high-risk group for cardiac manifestations associated with severe prognosis at all ages.
原纤维蛋白-1(FBN1)基因突变会导致马凡综合征(MFS),并与一系列重叠的表型相关。发病年龄的差异以及主动脉特征严重程度的广泛范围使得临床护理变得复杂。调节家族间和家族内表型严重程度的因素仍有待确定。国际FBN1突变通用突变数据库(UMD-FBN1)的可用性使我们能够开展有史以来最大规模的合作研究,以调查FBN1基因型与临床表型的性质和严重程度之间的相关性。对1013名携带致病性FBN1突变的先证者中不同类型(类型和位置)的突变,比较了一系列定性和定量的临床参数(骨骼、心血管、眼科、皮肤、肺部和硬脑膜)。与其他错义突变相比,发生替代或产生半胱氨酸的错义突变的患者发生晶状体异位的可能性更高。携带FBN1过早终止密码子的患者比框内突变患者具有更严重的骨骼和皮肤表型。外显子24 - 32中的突变与更严重和完整的表型相关,包括I型原纤维蛋白病诊断时年龄较小、发生晶状体异位、升主动脉扩张、主动脉手术、二尖瓣异常、脊柱侧凸的可能性更高以及生存期更短;即使排除新生儿MFS病例,这些结果中的大多数仍可重复。在不同突变类型与临床表现之间发现的这些相关性,可能由不同的潜在遗传机制(显性负效应与单倍体不足)以及对原纤维蛋白-1的两种主要生理功能(结构功能与转化生长因子β信号传导介质功能)的考虑来解释。外显子24 - 32突变定义了一个与各年龄段严重预后相关的心脏表现的高危组。
JACC Adv. 2025-8-8
J Mol Cell Cardiol Plus. 2025-6-19
Urol Case Rep. 2025-2-3
Front Pediatr. 2025-3-7
J Cell Biol. 2007-1-29
Surv Ophthalmol. 2006
N Engl J Med. 2006-8-24
Lancet. 2005-12-3
Hum Mutat. 2005-9
Nat Genet. 2004-8